Unlike the conventional chimeric antigen receptor (CAR) -T cell technology that relies on the use of patient blood cells to generate highly personalized αβ T cell-based therapy for certain cancers, our CAR-γδ T cell technology utilizes healthy donor blood cells to manufacture the “off-the-shelf” CTM-N2D therapy targeting stress-induced cancer antigens that is suitable for many patients across a wide spectrum of cancers.